{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-26-000151","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2026-08-05T20:07:39+00:00","discovered_at":"2026-08-05T20:09:00.248288+00:00","generated_at":"2026-08-05T20:10:23.230823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GoodRx Q2 revenue $200.4M, Pharma Direct +76% YoY; raises FY2026 guidance","bullets":["Revenue $200.4M; net income $8.5M (4.3% margin); adjusted EBITDA $63.7M (31.8% margin).","Pharma Direct revenue up 76% YoY; Subscription revenue up 39% YoY.","Company raises full-year 2026 revenue and adjusted EBITDA expectations.","Adjusted net income $26.8M (13.4% margin); net cash from operations $80.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-26-000151","json":"https://secwatch.observer/filing/0001809519-26-000151.json","markdown":"https://secwatch.observer/filing/0001809519-26-000151.md","text":"https://secwatch.observer/filing/0001809519-26-000151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/0001809519-26-000151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/gdrx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:10:23.230823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}